These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15469457)

  • 1. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.
    Briani C; Cagnin A; Chierichetti F; Tiberio M; Battistin L; Pizzolato G
    Eur J Neurol; 2004 Oct; 11(10):709-10. PubMed ID: 15469457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study.
    Boesch SM; Donnemiller E; Müller J; Seppi K; Weirich-Schwaiger H; Poewe W; Wenning GK
    Mov Disord; 2004 Nov; 19(11):1320-5. PubMed ID: 15390003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism.
    Radau PE; Linke R; Slomka PJ; Tatsch K
    J Nucl Med; 2000 Feb; 41(2):220-7. PubMed ID: 10688103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
    Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
    Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH
    Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation--preliminary results.
    Ebert D; Feistel H; Kaschka W; Barocka A; Pirner A
    Biol Psychiatry; 1994 Jun; 35(11):880-5. PubMed ID: 8054411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
    Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G
    Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.